Soligenix (SNGX) Depreciation & Amortization (CF) (2010 - 2026)
Soligenix's (SNGX) quarterly Depreciation & Amortization (CF) came in at $1098.0 in Q1 2026, up 80.59% YoY from $608.0 in Q1 2025, and up 9.58% on a QoQ basis from $1002.0 in Q4 2025.
Soligenix (SNGX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1098.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 80.59% year-over-year to $1098.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3714.0 (down 23.17% YoY) and the FY2025 annual result came in at $3224.0, down 44.55% from the prior year.
- Depreciation & Amortization (CF) rose to $1098.0 in Q1 2026, from $1002.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $8512.0 in Q2 2022 to a low of $608.0 in Q1 2025.
- A 5-year average of $2426.5 and a median of $1589.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 81.32% — and 2026, when it soared 80.59%.
- Tracing SNGX's Depreciation & Amortization (CF) over 5 years: stood at $3024.0 in 2022, then sank by 47.42% to $1590.0 in 2023, then sank by 34.03% to $1049.0 in 2024, then decreased by 4.48% to $1002.0 in 2025, then gained by 9.58% to $1098.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $1098.0 (Q1 2026), $1002.0 (Q4 2025), and $911.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,097.00 |
| Jun 30, 2026 | 1,097.00 |
| Mar 31, 2026 | 1,098.00 |
| Mar 31, 2026 | 1,098.00 |
| Dec 31, 2025 | 1,002.00 |
| Dec 31, 2025 | 1,002.00 |
| Sep 30, 2025 | 911.00 |
| Sep 30, 2025 | 911.00 |
| Jun 30, 2025 | 703.00 |
| Jun 30, 2025 | 703.00 |
| Mar 31, 2025 | 608.00 |
| Mar 31, 2025 | 608.00 |
| Dec 31, 2024 | 1,049.00 |
| Dec 31, 2024 | 1,049.00 |
| Sep 30, 2024 | 1,589.00 |
| Sep 30, 2024 | 1,589.00 |
| Jun 30, 2024 | 1,588.00 |
| Jun 30, 2024 | 1,588.00 |
| Mar 31, 2024 | 1,588.00 |
| Mar 31, 2024 | 1,588.00 |